1 recruiting. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Recruiting 1 |
Follow PMD: new trials by email Literature Review of PMD trials Research Report on PMD
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD" Elranatamab - Phase 2, Radiotherapy-Induced Immune Priming | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 34 | 2026-03-31 | 2026-09-18 |
Multiple Myeloma (1)
Blood Protein Disorders (1) · Cardiovascular Diseases (1) · Hematologic Diseases (1) · Hemic and Lymphatic Diseases (1) · Hemorrhagic Disorders (1) · Hemostatic Disorders (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Lymphoproliferative Disorders (1) · Neoplasms (1) · Neoplasms by Histologic Type (1) · Neoplasms, Plasma Cell (1) · Paraproteinemias (1) · Vascular Diseases (1)
M.D. Anderson Cancer Center (1)
United States (1)
Christine Ye, MD (1)